← Back to Clinical Trials
Recruiting NCT06681818

NCT06681818 Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06681818
Status Recruiting
Phase
Sponsor Englewood Hospital and Medical Center
Condition Liver Cancer Adult
Study Type INTERVENTIONAL
Enrollment 125 participants
Start Date 2025-11-21
Primary Completion 2039-01-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
carbon monoxide measurement via smokerlyzer

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 125 participants in total. It began in 2025-11-21 with a primary completion date of 2039-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

the investigators will pursue two specific aims: (1) to monitor the extent of heme oxygenase induction (by measuring endogenous CO production) in relationship to the extent of hepatic resection (2) to assess the production of CO in patients following liver resection and correlate these findings to the rate of liver regeneration and liver function.

Eligibility Criteria

Inclusion Criteria: * Patient plans to have partial liver resection for primary liver pathology or metastatic disease * Patient is able to comprehend and willing to sign the written consent form Exclusion Criteria: * Patients \< 18 years * Patients identified as members of a vulnerable population, except women of child bearing potential with negative pregnancy test

Contact & Investigator

Central Contact

Jamie Ketas

✉ jamie.ketas@ehmchealth.org

📞 2018943418

Principal Investigator

Cherif Boutros, MD

PRINCIPAL INVESTIGATOR

Englewood Hospital

Frequently Asked Questions

Who can join the NCT06681818 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Liver Cancer Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06681818 currently recruiting?

Yes, NCT06681818 is actively recruiting participants. Contact the research team at jamie.ketas@ehmchealth.org for enrollment information.

Where is the NCT06681818 trial being conducted?

This trial is being conducted at Englewood, United States.

Who is sponsoring the NCT06681818 clinical trial?

NCT06681818 is sponsored by Englewood Hospital and Medical Center. The principal investigator is Cherif Boutros, MD at Englewood Hospital. The trial plans to enroll 125 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology